摘要
阿尔茨海默病(AD)的生物标志物的发现是疾病治疗策略的关键。至目前为止,AD生物标志物的研究主要集中在脑成像和脑脊液(CSF)β-淀粉样蛋白(Aβ)肽和Tou蛋白的变化。通过纳入新的生物标志物优化其敏感性和特异性可以提高该组系列的可靠的程度。在这项研究中,我们确定在AD的进展中脑脊液神经生长因子(NGF)前体蛋白proNGF的水平是否升高,在临床诊断有轻度认知障碍(MCI)或AD的死者的脑组织样本的水平里反映有上调。紧急宗教团体研究中的参与者,临终前临床诊断为无认知功能障碍(NCI)、遗忘型MCI(aMCI、假定的AD先兆阶段)或轻/中度AD,从死者采集脑室脑脊液,运用免疫印迹分析进行测定。与NCI相比,aMCI 的proNGF水平增高55 %,AD 增高70%。脑脊液proNGF水平的升高与认知障碍测试的分数相关。在补充的研究中,我们发现与临床痴呆评定CDR = 0的患者相比,临床痴呆评定(CDR)= 0.5或1的患者的腰椎脑脊液CSF样本的proNGF水平显著增加 30%。值得注意的是,与对照组CDR= 0相比,CDR= 0.5或1的proNGF/Aβ1-42水平增高了50%。相比之下,aMCI和NCI患者脑脊液脑源性神经营养因子(BDNF)的ELISA测量值没有区别。总之,这些结果表明,proNGF蛋白水平可能增加目前用脑脊液的生物标志物面板有助诊断的的准确率。
关键词: 阿尔茨海默病,淀粉样蛋白,生物标志物,脑脊液,轻度认知功能障碍,神经生长因子前体,tau蛋白。
Current Alzheimer Research
Title:Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease
Volume: 13 Issue: 7
Author(s): Scott E. Counts, Bin He, John G. Prout, Bernadeta Michalski, Lucia Farotti, Margaret Fahnestock, Elliott J. Mufson
Affiliation:
关键词: 阿尔茨海默病,淀粉样蛋白,生物标志物,脑脊液,轻度认知功能障碍,神经生长因子前体,tau蛋白。
摘要: The discovery of biomarkers for the onset of Alzheimer’s disease (AD) is essential for disease modification strategies. To date, AD biomarker studies have focused on brain imaging and cerebrospinal fluid (CSF) changes in amyloid- β (Aβ) peptide and tau proteins. While reliable to an extent, this panel could be improved by the inclusion of novel biomarkers that optimize sensitivity and specificity. In this study, we determined whether CSF levels of the nerve growth factor (NGF) precursor protein, proNGF, increased during the progression of AD, mirroring its up regulation in postmortem brain samples of people who died with a clinical diagnosis of mild cognitive impairment (MCI) or AD. Immunoblot analysis was performed on ventricular CSF harvested from participants in the Rush Religious Orders Study with an antemortem clinical diagnosis of no cognitive impairment (NCI), amnestic MCI (aMCI, a putative prodromal AD stage), or mild/moderate AD. ProNGF levels were increased 55% in aMCI and 70% in AD compared to NCI. Increasing CSF proNGF levels correlated with impairment on cognitive test scores. In a complementary study, we found that proNGF was significantly increased by 30% in lumbar CSF samples derived from patients with a clinical dementia rating (CDR) of 0.5 or 1 compared to those with a CDR = 0. Notably, proNGF/Aβ1-42 levels were 50% higher in CDR 0.5 and CDR 1 compared to CDR 0 controls. By contrast, ELISA measurements of CSF brain-derived neurotrophic factor (BDNF) did not distinguish aMCI from NCI. Taken together, these results suggest that proNGF protein levels may augment the diagnostic accuracy of currently used CSF biomarker panels.
Export Options
About this article
Cite this article as:
Scott E. Counts, Bin He, John G. Prout, Bernadeta Michalski, Lucia Farotti, Margaret Fahnestock, Elliott J. Mufson , Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (7) . https://dx.doi.org/10.2174/1567205013666160129095649
DOI https://dx.doi.org/10.2174/1567205013666160129095649 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insights into Biological Markers of Frontotemporal Lobar Degeneration Spectrum
Current Medicinal Chemistry The Over-Under on the Misdiagnosis of Bipolar Disorder: A Systematic Review
Current Psychiatry Reviews Aqueous Extract of <i>Cola nitida</i> and <i>Garcinia kola</i> Synergistically Enhances Hippocampal-hypothalamic Glutamate and Na+ /K+ -ATPase Activity in Male Wistar Rats
Current Drug Discovery Technologies Brain-Derived Neurotrophic Factor: A Dynamic Gatekeeper of Neural Plasticity
Current Molecular Pharmacology Vaccine Development for Alzheimers Disease
Current Pharmaceutical Design Gene Control of Synaptic Plasticity and Memory Formation: Implications for Diseases and Therapeutic Strategies
Current Molecular Medicine Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Current Alzheimer Research Developing Novel Therapeutic Approaches to Frailty
Current Pharmaceutical Design Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions
Current Pharmacogenomics Editorial[Hot Topic:Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Current Medicinal Chemistry Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer’s Disease
Current Neurovascular Research Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research